Prophylactic treatment of dacomitinib‐induced skin toxicities in epidermal growth factor receptor‐mutated non–small‐cell lung cancer: A multicenter, Phase II trial

BACKGROUND: Dacomitinib significantly improves progression‐free survival and overall survival (OS) compared with gefitinib in patients with non–small‐cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR)‐activating mutations. However, dacomitinib often causes skin toxicities, re...

Descripción completa

Detalles Bibliográficos
Autores principales: Iwasaku, Masahiro, Uchino, Junji, Chibana, Kenji, Tanzawa, Shigeru, Yamada, Takahiro, Tobino, Kazunori, Uchida, Yasuki, Kijima, Takashi, Nakatomi, Katsumi, Izumi, Miiru, Tamiya, Nobuyo, Kimura, Hideharu, Fujita, Masaki, Honda, Ryoichi, Takumi, Chieko, Yamada, Tadaaki, Kaneko, Yoshiko, Kiyomi, Fumiaki, Takayama, Koichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10417098/
https://www.ncbi.nlm.nih.gov/pubmed/37269194
http://dx.doi.org/10.1002/cam4.6184

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10417098/
https://www.ncbi.nlm.nih.gov/pubmed/37269194
http://dx.doi.org/10.1002/cam4.6184

Ejemplares similares